UGT1A1 genotyping (TA6/TA7)

GENETIC2 trials

Sponsors

Kaohsiung Medical University Chung-Ho Memorial Hospital

Conditions

Colorectal CancerMetastatic Colorectal Cancer

Phase 2

Regorafenib Plus FOLFIRI With Irinotecan Dose Escalated in Patients With Previously Treated Metastatic Colorectal Cancer

Kaohsiung Medical University Chung-Ho Memorial HospitalMetastatic Colorectal Cancer

Start: 2019-02-26End: 2021-12-31Target: 153Updated: 2019-03-21

Unknown Phase

Metastatic Colorectal Cancer Treated With Regorafenib and FOLFIRI

CompletedNCT03698253

Kaohsiung Medical University Chung-Ho Memorial HospitalColorectal Cancer

Start: 2013-10-01End: 2018-06-01Updated: 2018-10-05

Related Papers

Efficacy and safety of regorafenib plus FOLFIRI with <i>UGT1A1</i> genotyping-guided irinotecan dose escalation against metastatic colorectal cancer: a multicenter, phase II, open-label, two-arm randomized controlled tria.

2025-10-23

Regorafenib plus FOLFIRI with irinotecan dose escalated according to uridine diphosphate glucuronosyltransferase 1A1genotyping in previous treated metastatic colorectal cancer patients:study protocol for a randomized controlled trial

Trials2019-12-018 citations